---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004062"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:03:19.015887+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy

## Summary
- Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.
- SER-155 Phase 1b biomarker: significant decrease in fecal albumin (epithelial barrier integrity) vs placebo.
- FDA granted Breakthrough Therapy designation for SER-155 in allo-HSCT in Dec 2024.
- Briefing Book submitted for next registrational study; FDA feedback expected Q1 2025.
- SER-155 results accepted for oral presentation at TANDEM Meeting Feb 2025.

## SEC filing metadata
- accession: 0001193125-25-004062
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525004062/0001193125-25-004062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525004062/d925391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004062
- JSON: https://secwatch.observer/filing/0001193125-25-004062.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.